Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
NIDDK Central Repository added a new study,
Novel Therapies for Resistant FSGS (primary focal segmental glomerulosclerosis): Phase II Clinical Trial (FONT II) and is available for request. Read information from NIDDK news.